Imperial Valley News Center
FDA warns company for selling e-liquids that resemble kid-friendly foods
- Details
- Written by Michael Felberbaum
Washington, DC - The U.S. Food and Drug Administration today issued a warning letter to Electric Lotus LLC for selling nicotine-containing e-liquids used in e-cigarettes with labeling and/or advertising that cause them to resemble kid-friendly food products, such as cereal, candy and peanut butter and jelly. The action is part of the agency’s ongoing effort to protect kids from tobacco products.
FDA approves first treatment for Lambert-Eaton myasthenic syndrome
- Details
- Written by Sandy Walsh
Washington, DC - The U.S. Food and Drug Administration Wednesday approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
President Donald J. Trump Signed H.R. 7187 into Law
- Details
- Written by White House
Washington, DC - On Saturday, December 1, 2018, the President signed into law:
World AIDS Day
- Details
- Written by Anne Rancourt
Washington, DC - NIH Statement on World AIDS Day December 1, 2018 by Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases and Maureen M. Goodenow, Ph.D., Director, Office of AIDS Research:
Meeting the challenge of engaging men in HIV prevention and treatment
- Details
- Written by IVN
Washington, DC - A new commentary from National Institutes of Health scientists asserts that engaging men in HIV prevention and care is essential to the goal of ending the HIV pandemic. The article by Adeola Adeyeye, M.D., M.P.A., and David Burns, M.D., M.P.H., of the National Institute of Allergy and Infectious Diseases (NIAID) and Michael Stirratt, Ph.D., of the National Institute of Mental Health (NIMH) also discusses potential solutions.
NIH to evaluate effectiveness of male contraceptive skin gel
- Details
- Written by Meredith Daly
Washington, DC - A clinical trial funded by the National Institutes of Health will evaluate a male contraceptive gel for its ability to prevent pregnancy. The gel formulation was developed by the Population Council and NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The Population Council will collaborate with NIH to conduct the study in NICHD’s Contraceptive Clinical Trials Network.
Page 947 of 3785